Stockreport

FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes Candidate [Yahoo! Finance]

Biomea Fusion, Inc.  (BMEA) 
PDF Phase 1/2 clinical trials of the company's investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively [Read more]